本帖最后由 老马 于 2012-1-13 21:20 编辑
1 m' o/ s$ G7 k5 @" E
- ?8 l0 F: R3 P* |; ]% p3 \爱必妥和阿瓦斯丁的比较
) s) G" T6 b6 W6 X4 ]
2 m' @( w, m1 \http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
6 I, m7 Z+ Z2 X \; l2 F
/ K+ H. s" B- n* J/ v7 Q: {
( s3 }$ [% q: f" O! c
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ d# {$ {! b, v) N==================================================% n6 N7 u1 s7 R8 m- e* _2 H
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 Z" ]+ g5 o4 m+ B/ t
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; ], a5 o, h) A) QResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# Y. S9 V4 h! g1 C0 t) B3 }/ S9 L# N
|